ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

The current status of the approved granulocyte colony-stimulating factors (G-CSFs) and granulocyte-macrophage colony-stimulating factors (GM-CSFs) was discussed during an Educational Symposium, entitled ‘Update on Growth Factors’ at the 31st Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Los Angeles, US, in May this year. In addition, data on new agents with thrombopoietic activity such as interleukin-1 (IL-1), IL-3, IL-6, IL-11, PIXY-321, SC-55464 and thrombopoietin were also presented. The reports focused on the use of these agents in providing haematopoietic support in patients with cancer who are undergoing antineoplastic chemotherapy that is likely to induce neutropenia and thrombocytopenia. Dr Langdon Miller, from the National Cancer Institute, Bethesda, US, summarises his own presentation from the session and provides an overview of the key points discussed by other speakers.

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

Many potential clinical indications have been identified for integrin antagonists. Integrins are cell adhesion molecules that are involved in numerous biochemical events. Specific integrins have now been identified for specific interactions. By directing antibodies against these molecules, researchers are opening up a whole new field of therapy. The majority of this research is still at the preclinical stage. However, some agents are now approaching clinical trials, as described at the 4th IBC conference on Cell Adhesion Molecules [San Francisco, US; May 1995].

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

Zileuton [Leutrol®; Abbott], a 5-lipoxygenase inhibitor, is close to being considered for approval by the US FDA for use in patients with chronic asthma. The efficacy of zileuton was discussed in several presentations at the Annual International Meeting of the American Lung Association and the American Thoracic Society [Seattle, US; May, 1995]. Dr Eliot Israel from Boston, US, reported that zileuton reduces the need for corticosteroid rescue in patients with acute exacerbations of asthma. Findings from another study indicated that zileuton is as effective as theophylline in improving forced expiratory volume (FEV1) and reducing &bgr;-agonist use in patients with moderate asthma. In addition, the effects of zileuton in children with asthma have been investigated for the first time in a single-dose pharmacokinetic study.

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS